StoneCrest Wealth Management’s AstraZeneca AZN Stock Holding History

StoneCrest Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$967K	Buy	+5,991	New	+$998K	0.31%	54

Other funds holding AZN

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

Primecap Management Pasadena, California $161B AUM 86.05% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

StoneCrest Wealth Management's AZN Position: Q3 2026 in Review

StoneCrest Wealth Management opened a new position in AstraZeneca (AZN) in Q3 2026: 5,991 shares worth $967K. The stake represents 0.31% of the portfolio and ranks #54 among its holdings.

1,116 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

StoneCrest Wealth Management held 5,991 shares of AstraZeneca worth $967K as of Q3 2026.
AstraZeneca was a new StoneCrest Wealth Management position in Q3 2026.
AstraZeneca made up 0.31% of StoneCrest Wealth Management's portfolio in Q3 2026, its #54 holding.
1,116 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on StoneCrest Wealth Management's 13F filing for Q3 2026, filed 3 Nov 2026.